Sou Hu Cai Jing·2025-04-01 11:17Group 1 - The core viewpoint of the articles highlights WuXi AppTec's current stock performance, with a closing price of 68.23 yuan, an increase of 1.35%, and a rolling PE ratio of 20.85 times, with a total market capitalization of 197.048 billion yuan [1] - The average PE ratio for the medical services industry is 52.86 times, with a median of 49.90 times, positioning WuXi AppTec at the 14th rank within the industry [1] - As of February 28, 2025, the number of shareholders for WuXi AppTec is 261,179, a decrease of 39,360 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - WuXi AppTec's main business is providing integrated, end-to-end drug research and development and manufacturing services for the global pharmaceutical and life sciences industry, with key products including chemical, testing, and biological services [1] - The latest financial results for the year 2024 show that the company achieved an operating revenue of 39.241 billion yuan, a year-on-year decrease of 2.73%, and a net profit of 9.450 billion yuan, a year-on-year decrease of 1.63%, with a gross profit margin of 41.48% [1] - The PE ratio for WuXi AppTec is 20.85 times, with a price-to-book ratio of 3.36, and a total market capitalization of 197.048 billion yuan [2]